We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lower HbA1c Levels Seen in Diabetic Liver Disease Patients

By LabMedica International staff writers
Posted on 23 May 2019
Diabetes is a leading cause of liver disease, with cirrhosis responsible for a considerable number of deaths in people with diabetes in the USA. More...
The association is mediated by multiple mechanisms including dyslipidemia and altered hepatic fatty acid processing.

Glycated hemoglobin or HbA1c is now widely used for this purpose in primary care, resulting in a doubling of the number of HbA1c assessments requested, and a corresponding decrease in glucose measurement. Since 2014, the use of HbA1c testing has been included in the American Diabetes Association guidelines for the diagnosis of diabetes in hospital.

Scientists at the Queen Elizabeth Hospital (Birmingham, UK) and their colleagues collected HbA1c and random plasma glucose data for 125 people with diabetes without liver disease and for 29 people awaiting liver transplant with diabetes and cirrhosis. Cirrhosis was caused by non‐alcoholic fatty liver disease, hepatitis C, alcoholic liver disease, hereditary hemochromatosis, polycystic liver/kidneys, cryptogenic/non‐cirrhotic portal hypertension and α‐1‐antitrypsin‐related disease.

The team measured biochemical variables on the Roche c8000 analyzers and full blood count on Beckman DxH800 analyzers. HbA1c was measured in EDTA blood using an International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) aligned TOSOH G8 ion exchange high performance liquid chromatography analyzers.

The scientists reported that the median (interquartile range) HbA1c was 41 (32–56) mmol/mol [5.9%] (5.1–7.3) versus 61 (52–70) mmol/mol [7.7 (6.9–8.6) %] respectively, in the diabetes with cirrhosis group versus the diabetes without cirrhosis group. The glucose concentrations were 8.4 (7.0–11.2) mmol/L versus 7.3 (5.2–11.5) mmol/L. HbA1c was depressed by 20 mmol/mol (1.8%) in 28 participants with cirrhosis but elevated by 28 mmol/mol (2.6%) in the participant with α‐1‐antitrypsin disorder. Those with cirrhosis and depressed HbA1c had fewer larger erythrocytes, and higher red cell distribution width and reticulocyte count. This was reflected in the positive association of glucose with mean cell volume and hemoglobin level and the negative association for HbA1c in the diabetes group with cirrhosis.

The authors concluded that cirrhosis of the liver affects the accuracy of HbA1c results, leading to unreliable estimates of blood glucose over the previous 2 to 3 months. Anemia in people with cirrhosis awaiting liver transplant is associated with altered red blood cell morphology. The study was originally published in the May 2019 issue of the journal Diabetic Medicine.

Related Links:
Queen Elizabeth Hospital


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.